Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and
the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma.
Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be
evaluated.